What should a minimum adequate follow-up protocol look like for patients following CAR-T therapy, and who should be responsible for it once a patient is years out from infusion and asymptomatic?
This question is part of our collaboration with ACR Convergence 2026 to preview a session from this year's meeting. This question is inspired by the session series: "Cellular Immunotherapy: Are We on the Cusp of a Therapeutic Revolution in Rheumatology?
2 Answers
Mednet MemberInvited Expert
Rheumatology · University of Michigan
Answered on
A minimum adequate follow-up protocol after CAR-T therapy should be structured, risk-adapted, and jointly managed by rheumatology and the cellular-therapy center. During the first 30–100 days, the cellular-therapy team should lead monitoring for cytokine release syndrome, immune effector cell–associ...
Join for free or sign in to see the full answer
Mednet Member
Rheumatology · University of Cincinnati
Answered on
By law, the follow-up is 15 years, and the company/institution providing the medication/CAR-T cells is responsible for making this happen.
Join for free or sign in to see the full answer